Thalidomide analogs as emerging anti-cancer drugs

Anti-Cancer Drugs

Volumn 14, Issue 5, 2003, Pages 331-335

  Dredge, Keith ^a   Dalgleish, Angus G ^a   Marriott, J Blake ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti angiogenic; Anti inflammatory; Anti tumor; Co stimulatory; Thalidomide analogs

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ANTINEOPLASTIC AGENT; CC 1088; CC 7085; CC 8490; LENALIDOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; SHORT SURVEY; SIDE EFFECT; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; THALIDOMIDE;

EID: 0038178919     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200306000-00001     Document Type: Short Survey

References (31)

1. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12:564-573.
2. Gasparini G, Morabito A, Magnani E, Gattuso D, Capaccetti B, Alberti AM. Thalidomide: an old sedative-hypnotic with anticancer activity? Curr Opin Invest Drugs 2001; 2:1302-1308.
3. Raje N, Anderson KC. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002; 14:635-640.
4. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999; 341:1565-1571.
5. Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother 2002; 56:115-128.
6. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996; 39:3238-3240.
7. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2:506-515.
8. Muller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Stirling DI. Thalidomide analogs and PDE4 inhibition, Bioorg Med Chem Lett 1998; 8:2669-2674.
9. Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9:1625-1630.
10. Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, et al. CC-3052: a water soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol 1998; 161:4236-4243.
11. Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, et al. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res 2003; 63:593-599.
12. b1 -type immunity. J Immunol 2002; 168:4914-4919.
13. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, et al. Novel thalidomide analogs display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87:1166-1172.
14. Raje N, Anderson KC. Thalidomide and Immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002; 14:635-640.
15. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99:4525-4230.
16. + subset. J Exp Med 1998; 187:1885-1892.
17. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of Thalidomide analogs that are potent inhibitors of TNF-α. J Immunol 1999; 163:380-386.
18. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159:5157-5161.
19. + cells. Clin Exp Immunol 2002; 130:75-84.
20. Noguchi T, Shimazawa R, Nagasawa K, Hashimoto Y. Thalidomide and its analogues as cyclooxygenase inhibitors. Bio Med Chem Lett 2002; 12:1043-1046.
21. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Can Res 2001; 7:3349-3355.
22. Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 2002; 62:2300-2305.
23. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17:41-44.
24. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neuro-Oncol 1999; 43:109-114.
25. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2002; 96:2943-2950.
26. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15:1950-1961.
27. Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW, et al. Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis. J Med Chem 2002; 42:3014-3017.
28. Richardson PG, Schlossman RL, Weller E, Hideshima T, Lentzsch S, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma (MM). Blood 2002; 100:3062-3067.
29. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B, Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood 2001; 98:775a.
30. Schey SA, Jones RW, Raj K, Streetley M. A phase I study of an immunomodulatory drug (CC-4047), a structural analogue of thalidomide, in relapsed/refractory multiple myeloma. In: Proc 31st Annu Meet Int Soc Exp Haematol 2002.
31. Marriott JB, Clarke IA, Dredge K, Pandha H, Kristaleit H, Polychronis A, et al. Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation. Br J Cancer 2002; 86:S26-S26.